Credit Suisse Group Analysts Give Allergan PLC. (NYSE:AGN) a $288.00 Price Target
AGN has been the topic of several other reports. UBS AG restated a buy rating and set a $275.00 price objective on shares of Allergan PLC. in a report on Monday, May 15th. Vetr upgraded Allergan PLC. from a sell rating to a hold rating and set a $242.88 price objective on the stock in a report on Monday, June 26th. Royal Bank Of Canada set a $284.00 price objective on Allergan PLC. and gave the stock a buy rating in a report on Monday, June 12th. BidaskClub upgraded Allergan PLC. from a hold rating to a buy rating in a report on Saturday, June 24th. Finally, Mizuho restated a buy rating and set a $267.00 price objective on shares of Allergan PLC. in a report on Wednesday, August 2nd. Seven research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Allergan PLC. has an average rating of Buy and an average price target of $274.14.
Shares of Allergan PLC. (NYSE:AGN) opened at 241.22 on Friday. The company has a market capitalization of $81.02 billion, a price-to-earnings ratio of 7.52 and a beta of 1.16. The company’s 50 day moving average price is $245.21 and its 200 day moving average price is $237.12. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80.
Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. Allergan PLC.’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period last year, the business posted $3.35 EPS. On average, analysts predict that Allergan PLC. will post $16.20 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be given a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.16%. Allergan PLC.’s payout ratio is 9.95%.
In other news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.36% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of AGN. Veritas Asset Management LLP purchased a new stake in shares of Allergan PLC. during the first quarter worth approximately $761,339,000. Edgewood Management LLC boosted its stake in shares of Allergan PLC. by 7.0% in the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock worth $646,090,000 after buying an additional 178,055 shares in the last quarter. Epoch Investment Partners Inc. boosted its stake in shares of Allergan PLC. by 3.8% in the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock worth $481,045,000 after buying an additional 73,081 shares in the last quarter. UBS Asset Management Americas Inc. boosted its stake in shares of Allergan PLC. by 0.3% in the first quarter. UBS Asset Management Americas Inc. now owns 1,995,281 shares of the company’s stock worth $476,713,000 after buying an additional 5,042 shares in the last quarter. Finally, Blue Ridge Capital L.L.C. boosted its stake in shares of Allergan PLC. by 24.1% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock worth $456,313,000 after buying an additional 370,400 shares in the last quarter. 84.77% of the stock is owned by hedge funds and other institutional investors.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.